CTLA4 and melanoma: We were surprised to discover that the low-risk group is likely to respond to anti-PD-1 treatment, whereas the high-risk group is insensitive to anti-CTLA-4 treatment, which could supply effective solutions to aid in the final clinical decision and help patients with advanced melanoma achieve the highest remission rate.